Literature DB >> 8499944

Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines.

L B Andersen1, J W Fountain, D H Gutmann, S A Tarlé, T W Glover, N C Dracopoli, D E Housman, F S Collins.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant disorder characterized by progressive and variable involvement of tissues predominantly derived from the neural crest and a predisposition toward malignancies. The NF1 gene encodes neurofibromin, a GTPase-activating protein containing a GAP-related domain (NF1-GRD) that is capable of down-regulating ras by stimulating its intrinsic GTPase activity. We report a homozygous deletion of most of NF1 in one of eight malignant melanoma cell lines leading to loss of detectable mRNA and protein, as well as the apparent absence of protein and mRNA in another melanoma. This data suggests that NF1 can function as a tumour suppressor gene in the development or progression of malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499944     DOI: 10.1038/ng0293-118

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  42 in total

1.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

Authors:  E Serra; S Puig; D Otero; A Gaona; H Kruyer; E Ars; X Estivill; C Lázaro
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

Review 2.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

3.  Neurofibromatosis: chronological history and current issues.

Authors:  João Roberto Antônio; Eny Maria Goloni-Bertollo; Lívia Arroyo Trídico
Journal:  An Bras Dermatol       Date:  2013 May-Jun       Impact factor: 1.896

4.  A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.

Authors:  Scott A Stuart; Stephane Houel; Thomas Lee; Nan Wang; William M Old; Natalie G Ahn
Journal:  Mol Cell Proteomics       Date:  2015-04-07       Impact factor: 5.911

5.  C-->U editing of neurofibromatosis 1 mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme.

Authors:  Debnath Mukhopadhyay; Shrikant Anant; Robert M Lee; Susan Kennedy; David Viskochil; Nicholas O Davidson
Journal:  Am J Hum Genet       Date:  2001-11-27       Impact factor: 11.025

Review 6.  Clinical and genetic patterns of neurofibromatosis 1 and 2.

Authors:  N K Ragge
Journal:  Br J Ophthalmol       Date:  1993-10       Impact factor: 4.638

7.  Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Authors:  Moriah H Nissan; Christine A Pratilas; Alexis M Jones; Ricardo Ramirez; Helen Won; Cailian Liu; Shakuntala Tiwari; Li Kong; Aphrothiti J Hanrahan; Zhan Yao; Taha Merghoub; Antoni Ribas; Paul B Chapman; Rona Yaeger; Barry S Taylor; Nikolaus Schultz; Michael F Berger; Neal Rosen; David B Solit
Journal:  Cancer Res       Date:  2014-02-27       Impact factor: 12.701

Review 8.  Molecular genetics of neurofibromatosis type 1 (NF1).

Authors:  M H Shen; P S Harper; M Upadhyaya
Journal:  J Med Genet       Date:  1996-01       Impact factor: 6.318

9.  An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.

Authors:  Geoffrey T Gibney; Keiran S M Smalley
Journal:  Cancer Discov       Date:  2013-03       Impact factor: 39.397

10.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.